# ReViral

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/reviral

- Industry: Pharmaceuticals
- Headquarters: UK
- Website: www.reviral.co.uk
- Total disclosed funding: $125M
- Latest round: Series C (Aug 25, 2020)
- Investors on record: 8

## About

ReViral Ltd. is a biotechnology company focused on developing innovative therapies for viral infections, with a particular emphasis on respiratory syncytial virus (RSV) treatments.ReViral Ltd. was founded in 2011 in the UK, specializing in antiviral therapeutics. In April 2022, Pfizer Inc. agreed to acquire the company for approximately USD 525 mn, with the transaction aimed at advancing the clinical development of its RSV disease therapy.ReViral Ltd. specializes in developing antiviral therapies, particularly targeting respiratory syncytial virus (RSV). Its primary offerings focus on innovative treatment options designed to address this significant viral infection, enhancing patient outcomes and improving healthcare solutions.In 2022, ReViral Ltd. reported a revenue of USD 7,596,122.70, with an EBITDA of USD -763,458.70 for the year 2023.Following the recent acquisition by Pfizer Inc. in April 2022, ReViral Ltd. will leverage the USD 525 mn funding to enhance the clinical development of its RSV therapies. The company aims to accelerate the launch of new product offerings and expand its market presence in the global antiviral therapeutics landscape.

## Funding rounds

- Series C, Aug 25, 2020, $47M — OrbiMed Advisors, Andera Partners, New Leaf Venture Partners, Novo Holdings, CR Capital, Perceptive Advisors, Brace Pharma Capital, Green Sands Equity
- Series B, Jul 11, 2018, $55M — OrbiMed Advisors, Andera Partners, New Leaf Venture Partners, Novo Holdings, Perceptive Advisors, Brace Pharma Capital
- Series A, Sep 3, 2015, $24M — OrbiMed Advisors, Andera Partners, Brace Pharma Capital

## Investors

- OrbiMed Advisors (https://capitalatlas.ai/funds/orbimed-advisors) — Series A, Series B, Series C
- Andera Partners (https://capitalatlas.ai/funds/andera-partners) — Series A, Series B, Series C
- Brace Pharma Capital (https://capitalatlas.ai/funds/brace-pharma-capital) — Series A, Series B, Series C
- New Leaf Venture Partners (https://capitalatlas.ai/funds/new-leaf-venture-partners) — Series B, Series C
- Novo Holdings — Series B, Series C
- Perceptive Advisors (https://capitalatlas.ai/funds/perceptive-advisors) — Series B, Series C
- CR Capital (https://capitalatlas.ai/funds/cr-capital) — Series C
- Green Sands Equity (https://capitalatlas.ai/funds/green-sands-equity) — Series C